CN104447657B - 具有抗肿瘤活性的色烯酮衍生物 - Google Patents
具有抗肿瘤活性的色烯酮衍生物 Download PDFInfo
- Publication number
- CN104447657B CN104447657B CN201410654983.0A CN201410654983A CN104447657B CN 104447657 B CN104447657 B CN 104447657B CN 201410654983 A CN201410654983 A CN 201410654983A CN 104447657 B CN104447657 B CN 104447657B
- Authority
- CN
- China
- Prior art keywords
- chromene
- ethyl
- oxo
- morpholino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Cc1c(C*)c(OC(c2ccccc2)=O)c(*)c(*)c1* Chemical compound *Cc1c(C*)c(OC(c2ccccc2)=O)c(*)c(*)c1* 0.000 description 3
- VXVUBWLCPAQRJT-GATIEOLUSA-N CC(/C(/C(CC(N1CCOCC1)=C1)=C(C)C1=O)=C/C(C(N(C)C)=O)=C)Nc1cc(F)cc(OC)c1 Chemical compound CC(/C(/C(CC(N1CCOCC1)=C1)=C(C)C1=O)=C/C(C(N(C)C)=O)=C)Nc1cc(F)cc(OC)c1 VXVUBWLCPAQRJT-GATIEOLUSA-N 0.000 description 1
- JDEUJLRKKLWIRM-UHFFFAOYSA-N CC(C(C(OC(N1CCOCC1)=C1)=C(C2)C1=[U])=CC2C(N(C)C)=O)=O Chemical compound CC(C(C(OC(N1CCOCC1)=C1)=C(C2)C1=[U])=CC2C(N(C)C)=O)=O JDEUJLRKKLWIRM-UHFFFAOYSA-N 0.000 description 1
- FFISUGJJSCPMLM-UHFFFAOYSA-N CC(C(CC(C(N(C)C)=O)=C1)C(OC(N2CCOCC2)=C2)=C1C2=[U])Nc(cc1)ccc1F Chemical compound CC(C(CC(C(N(C)C)=O)=C1)C(OC(N2CCOCC2)=C2)=C1C2=[U])Nc(cc1)ccc1F FFISUGJJSCPMLM-UHFFFAOYSA-N 0.000 description 1
- UUIQQNYNMJPESN-UHFFFAOYSA-N CC(c(cc(cc12)C(N(C)C)=O)c1OC(N1CCOCC1)=CC2=O)Nc1cc(Cl)ccc1C Chemical compound CC(c(cc(cc12)C(N(C)C)=O)c1OC(N1CCOCC1)=CC2=O)Nc1cc(Cl)ccc1C UUIQQNYNMJPESN-UHFFFAOYSA-N 0.000 description 1
- CRLMTNXLTUSOPJ-UHFFFAOYSA-N CC(c(cc(cc12)C(O)=O)c1OC(N1CCOCC1)=CC2=O)=O Chemical compound CC(c(cc(cc12)C(O)=O)c1OC(N1CCOCC1)=CC2=O)=O CRLMTNXLTUSOPJ-UHFFFAOYSA-N 0.000 description 1
- MDHQZDJGSZVTDR-UHFFFAOYSA-N CC(c1cc(C(N(C)C)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc(cc(cc1)F)c1F Chemical compound CC(c1cc(C(N(C)C)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc(cc(cc1)F)c1F MDHQZDJGSZVTDR-UHFFFAOYSA-N 0.000 description 1
- XJSKZRBOYRXUSG-UHFFFAOYSA-N CC(c1cc(C(N(C)C)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc1cc(C)cc(F)c1 Chemical compound CC(c1cc(C(N(C)C)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc1cc(C)cc(F)c1 XJSKZRBOYRXUSG-UHFFFAOYSA-N 0.000 description 1
- ADXXTOWOZCJPQZ-PXYINDEMSA-N CC(c1cc(C(N(C)C)=O)cc2c1OC(N1C[C@H](C)OCC1)=CC2=O)Br Chemical compound CC(c1cc(C(N(C)C)=O)cc2c1OC(N1C[C@H](C)OCC1)=CC2=O)Br ADXXTOWOZCJPQZ-PXYINDEMSA-N 0.000 description 1
- GMWIXYJWVBNHHV-VYRBHSGPSA-N CC(c1cc(C(N(C)C)=O)cc2c1OC(N1C[C@H](C)OCC1)=CC2=O)Nc(cc1)ccc1F Chemical compound CC(c1cc(C(N(C)C)=O)cc2c1OC(N1C[C@H](C)OCC1)=CC2=O)Nc(cc1)ccc1F GMWIXYJWVBNHHV-VYRBHSGPSA-N 0.000 description 1
- UOZWDNWNBWHNIU-UHFFFAOYSA-N CC(c1cc(C(N(CC2)CCC2O)=O)cc2c1OC(N1CCOCC1)=CC2=O)N(C)c1cc(F)cc(F)c1 Chemical compound CC(c1cc(C(N(CC2)CCC2O)=O)cc2c1OC(N1CCOCC1)=CC2=O)N(C)c1cc(F)cc(F)c1 UOZWDNWNBWHNIU-UHFFFAOYSA-N 0.000 description 1
- QWELDBADLWQWPE-UHFFFAOYSA-N CC(c1cc(C(N(CC2)CCC2O)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc(cccc1Cl)c1F Chemical compound CC(c1cc(C(N(CC2)CCC2O)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc(cccc1Cl)c1F QWELDBADLWQWPE-UHFFFAOYSA-N 0.000 description 1
- GGAFSGSDUHLION-UHFFFAOYSA-N CC(c1cc(C(N(CC2)CCC2OC(C(C(C)(C)C)c2ccccc2)c2ccccc2)=O)cc2c1OC(N1CCOCC1)=CC2=O)N(C)c1cc(F)cc(F)c1 Chemical compound CC(c1cc(C(N(CC2)CCC2OC(C(C(C)(C)C)c2ccccc2)c2ccccc2)=O)cc2c1OC(N1CCOCC1)=CC2=O)N(C)c1cc(F)cc(F)c1 GGAFSGSDUHLION-UHFFFAOYSA-N 0.000 description 1
- MIIUCQQOKMDLDH-UHFFFAOYSA-N CC(c1cc(C(O)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc(cccc1Cl)c1F Chemical compound CC(c1cc(C(O)=O)cc2c1OC(N1CCOCC1)=CC2=O)Nc(cccc1Cl)c1F MIIUCQQOKMDLDH-UHFFFAOYSA-N 0.000 description 1
- CMKUQYFGGFUXTG-CBCUQQMYSA-N CC(c1cc(C(OC)=O)cc2c1OC(N1[C@@H](C)COCC1)=CC2=O)NC(C1)=CC(F)=CC1F Chemical compound CC(c1cc(C(OC)=O)cc2c1OC(N1[C@@H](C)COCC1)=CC2=O)NC(C1)=CC(F)=CC1F CMKUQYFGGFUXTG-CBCUQQMYSA-N 0.000 description 1
- GVSMCIMUFWNFGS-UHFFFAOYSA-N CCS(C(OC1C2=CC(C(OC)=O)=CC1C(C)Nc1cc([I]=C)cc([FH+])c1)=CC2=O)=O Chemical compound CCS(C(OC1C2=CC(C(OC)=O)=CC1C(C)Nc1cc([I]=C)cc([FH+])c1)=CC2=O)=O GVSMCIMUFWNFGS-UHFFFAOYSA-N 0.000 description 1
- USOBLPBXNCSJAQ-UHFFFAOYSA-N CCSC(Oc(c(Br)c1)c2cc1C([U]C)=O)=CC2=O Chemical compound CCSC(Oc(c(Br)c1)c2cc1C([U]C)=O)=CC2=O USOBLPBXNCSJAQ-UHFFFAOYSA-N 0.000 description 1
- HARBVWHVQRDBJR-BHWOMJMDSA-N CCc1cc(NC(C)c2cc(C(N(C)C)=O)cc3c2OC(N2[C@@H](C)COCC2)=CC3=O)cc(F)c1 Chemical compound CCc1cc(NC(C)c2cc(C(N(C)C)=O)cc3c2OC(N2[C@@H](C)COCC2)=CC3=O)cc(F)c1 HARBVWHVQRDBJR-BHWOMJMDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306017.6 | 2009-10-27 | ||
| EP09306017 | 2009-10-27 | ||
| CN201080060262.7A CN102712615B (zh) | 2009-10-27 | 2010-10-25 | 具有抗肿瘤活性的色烯酮衍生物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080060262.7A Division CN102712615B (zh) | 2009-10-27 | 2010-10-25 | 具有抗肿瘤活性的色烯酮衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104447657A CN104447657A (zh) | 2015-03-25 |
| CN104447657B true CN104447657B (zh) | 2016-08-17 |
Family
ID=43085922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410654983.0A Expired - Fee Related CN104447657B (zh) | 2009-10-27 | 2010-10-25 | 具有抗肿瘤活性的色烯酮衍生物 |
| CN201080060262.7A Expired - Fee Related CN102712615B (zh) | 2009-10-27 | 2010-10-25 | 具有抗肿瘤活性的色烯酮衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080060262.7A Expired - Fee Related CN102712615B (zh) | 2009-10-27 | 2010-10-25 | 具有抗肿瘤活性的色烯酮衍生物 |
Country Status (41)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| UY34013A (es) * | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ?compuestos de cromenona con actividad anti-tumoral?. |
| PE20151979A1 (es) | 2013-01-23 | 2016-01-15 | Astrazeneca Ab | Compuestos quimicos |
| MX362905B (es) | 2013-03-04 | 2019-02-25 | Astrazeneca Ab | Tratamiento de combinacion. |
| BR112016028876A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. |
| JP6454736B2 (ja) | 2014-06-13 | 2019-01-16 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| WO2015191754A2 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| ES2763103T3 (es) | 2014-06-13 | 2020-05-27 | Gilead Sciences Inc | Inhibidor de la fosfatidilinositol 3-quinasa |
| CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| BR112018007068B1 (pt) * | 2015-10-09 | 2024-01-02 | Janssen Pharmaceutica N.V. | Derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta, seu uso e composição farmacêutica que os compreende |
| WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| KR20210141214A (ko) * | 2020-05-15 | 2021-11-23 | 제이투에이치바이오텍 (주) | 3원환 화합물 및 이의 의약 용도 |
| IL304895A (en) * | 2021-02-01 | 2023-10-01 | Geode Therapeutics Inc | INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment |
| MX2023013080A (es) * | 2021-05-03 | 2023-11-16 | Petra Pharma Corp | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. |
| JP7759964B2 (ja) * | 2021-05-03 | 2025-10-24 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 |
| WO2022251482A1 (en) * | 2021-05-27 | 2022-12-01 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer |
| TW202329930A (zh) * | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| CA3232906A1 (en) * | 2021-10-07 | 2023-04-13 | Alessandro Boezio | Pi3k-alpha inhibitors and methods of use thereof |
| CA3237760A1 (en) * | 2021-12-08 | 2023-06-15 | Xiaolin Hao | Fused heterocyclic compounds as pi3kalpha inhibitors |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
| EP4602031A1 (en) * | 2022-10-14 | 2025-08-20 | Genesis Therapeutics, Inc. | Methods for treating cancer |
| CN119431297A (zh) * | 2023-08-02 | 2025-02-14 | 郑州同源康医药有限公司 | 稠环类化合物及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6027A (en) * | 1849-01-09 | Rotary blacksmith s twyer | ||
| AU634994B2 (en) | 1988-12-21 | 1993-03-11 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| DK0525123T3 (da) | 1990-06-20 | 1998-05-04 | Upjohn Co | Antiatherosklerotiske og antithrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| DE60128655T2 (de) | 2000-01-24 | 2008-02-07 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| CA2495661C (en) * | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| AU2006303037A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
| CN101448505A (zh) * | 2006-04-04 | 2009-06-03 | 加利福尼亚大学董事会 | Pi3激酶拮抗剂 |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| EP2112145A1 (en) | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
| WO2010134082A1 (en) | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2010
- 2010-10-22 US US12/909,968 patent/US8399460B2/en active Active
- 2010-10-25 CN CN201410654983.0A patent/CN104447657B/zh not_active Expired - Fee Related
- 2010-10-25 MY MYPI2012001831A patent/MY179833A/en unknown
- 2010-10-25 JP JP2012535931A patent/JP5657010B2/ja not_active Expired - Fee Related
- 2010-10-25 MX MX2012005027A patent/MX2012005027A/es active IP Right Grant
- 2010-10-25 ES ES10769052T patent/ES2530943T3/es active Active
- 2010-10-25 RS RS20150090A patent/RS53813B1/sr unknown
- 2010-10-25 EA EA201200618A patent/EA020523B9/ru not_active IP Right Cessation
- 2010-10-25 BR BR112012010124A patent/BR112012010124B8/pt not_active IP Right Cessation
- 2010-10-25 PL PL10769052T patent/PL2493870T3/pl unknown
- 2010-10-25 HR HRP20150146TT patent/HRP20150146T1/hr unknown
- 2010-10-25 IN IN3328DEN2012 patent/IN2012DN03328A/en unknown
- 2010-10-25 KR KR1020127012933A patent/KR101738195B1/ko not_active Expired - Fee Related
- 2010-10-25 ME MEP-2015-21A patent/ME02050B/me unknown
- 2010-10-25 NZ NZ599457A patent/NZ599457A/en not_active IP Right Cessation
- 2010-10-25 UA UAA201206000A patent/UA107474C2/uk unknown
- 2010-10-25 DK DK10769052.1T patent/DK2493870T3/en active
- 2010-10-25 SI SI201030875T patent/SI2493870T1/sl unknown
- 2010-10-25 CA CA2776994A patent/CA2776994C/en active Active
- 2010-10-25 AU AU2010311107A patent/AU2010311107B9/en not_active Ceased
- 2010-10-25 WO PCT/GB2010/051788 patent/WO2011051704A1/en not_active Ceased
- 2010-10-25 CN CN201080060262.7A patent/CN102712615B/zh not_active Expired - Fee Related
- 2010-10-25 PH PH1/2012/500804A patent/PH12012500804A1/en unknown
- 2010-10-25 PT PT10769052T patent/PT2493870E/pt unknown
- 2010-10-25 EP EP10769052.1A patent/EP2493870B1/en active Active
- 2010-10-25 PE PE2012000578A patent/PE20130149A1/es active IP Right Grant
- 2010-10-26 AR ARP100103937 patent/AR078786A1/es active IP Right Grant
- 2010-10-27 TW TW099136762A patent/TWI483939B/zh not_active IP Right Cessation
- 2010-10-27 SA SA110310808A patent/SA110310808B1/ar unknown
- 2010-10-27 UY UY32978A patent/UY32978A/es not_active Application Discontinuation
-
2012
- 2012-04-15 IL IL219191A patent/IL219191A0/en not_active IP Right Cessation
- 2012-04-25 CL CL2012001056A patent/CL2012001056A1/es unknown
- 2012-04-26 CO CO12068977A patent/CO6541528A2/es active IP Right Grant
- 2012-04-27 NI NI201200081A patent/NI201200081A/es unknown
- 2012-04-27 EC ECSP12011838 patent/ECSP12011838A/es unknown
- 2012-04-27 CR CR20120217A patent/CR20120217A/es unknown
- 2012-04-27 HN HN2012000889A patent/HN2012000889A/es unknown
- 2012-04-27 GT GT201200126A patent/GT201200126A/es unknown
- 2012-04-27 DO DO2012000124A patent/DOP2012000124A/es unknown
- 2012-04-27 CU CU2012000069A patent/CU20120069A7/es unknown
-
2013
- 2013-02-13 US US13/765,850 patent/US8673906B2/en active Active
-
2014
- 2014-01-24 US US14/163,105 patent/US9029374B2/en active Active
- 2014-11-20 JP JP2014235289A patent/JP5872016B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-12 SM SM201500036T patent/SMT201500036B/xx unknown
- 2015-02-13 CY CY20151100157T patent/CY1116143T1/el unknown
- 2015-04-08 US US14/681,244 patent/US20160060240A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/079,633 patent/US9718800B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Enamines in the Synthesis of 2-(Substituted Amino)-3,3-dialkylchromanones;Francis M.Dean,et al;《J. CHEM. SOC. PERKIN TRANS. I》;19821231;第2771-2775页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104447657B (zh) | 具有抗肿瘤活性的色烯酮衍生物 | |
| CN103596948B (zh) | 用于治疗癌症的作为pi3-激酶抑制剂的苯并吡喃酮化合物 | |
| HK1206335B (en) | Chromenone derivatives with anti-tumour activity | |
| HK1174027B (en) | Chromenone derivatives with anti-tumour activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1206335 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1206335 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160817 |